C
Christopher E. Heise
Researcher at Genentech
Publications - 28
Citations - 4350
Christopher E. Heise is an academic researcher from Genentech. The author has contributed to research in topics: Receptor & Kinase. The author has an hindex of 18, co-authored 28 publications receiving 4061 citations. Previous affiliations of Christopher E. Heise include University of Virginia.
Papers
More filters
Journal ArticleDOI
The immune modulator FTY720 targets sphingosine 1-phosphate receptors.
Volker Brinkmann,Michael Davis,Christopher E. Heise,R. Albert,Sylvain Cottens,Robert Paul Hof,Christian Bruns,Eva Prieschl,Thomas Baumruker,Peter Hiestand,Carolyn An Foster,Markus Zollinger,Kevin R. Lynch +12 more
TL;DR: The results suggest that FTY720, after phosphorylation, acts through sphingosine 1-phosphate signaling pathways to modulate chemotactic responses and lymphocyte trafficking.
Journal ArticleDOI
Characterization of the human cysteinyl leukotriene 2 receptor.
Christopher E. Heise,Brian F. O'Dowd,David J. Figueroa,Nicole Sawyer,Tuan V. Nguyen,Dong Soon Im,Rino Stocco,Julie N. Bellefeuille,Mark Abramovitz,Regina Cheng,David L. Williams,Zhizhen Zeng,Qingyun Liu,Lei Ma,Michelle K. Clements,Nathalie Coulombe,Yuan Liu,Christopher P. Austin,Susan R. George,Gary P. O'Neill,Kathleen M. Metters,Kevin R. Lynch,Jilly F. Evans +22 more
TL;DR: The cloning and characterization of the second cysteinyl leukotriene receptor, CysLT2, a 346-amino acid protein with 38% amino acid identity to the Cys LT1 receptor is described and demonstrated high affinity binding and a rank order of potency for competition of LTC4 = LTD4 ≫ LTE4.
Journal ArticleDOI
Characterization of a novel sphingosine 1-phosphate receptor, Edg-8.
Dong-Soon Im,Christopher E. Heise,Nicolas Ancellin,Brian F. O'Dowd,Gan-Ju Shei,Robert P. Heavens,Michael Rigby,Timothy Hla,Suzanne M. Mandala,George McAllister,Susan R. George,Kevin R. Lynch +11 more
TL;DR: The cloned and characterized Edg-8 is a high affinity sphingosine 1-phosphate receptor that couples to Gi/oα proteins and is expressed predominantly by oligodendrocytes and/or fibrous astroCytes in the rat brain.
Journal ArticleDOI
Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability
Benjamin E.L. Lauffer,Robert Mintzer,Rina Fong,Susmith Mukund,Christine Tam,Inna Zilberleyb,Birgit Flicke,Allegra Ritscher,Grazyna Fedorowicz,Roxanne Vallero,Daniel F. Ortwine,Janet L. Gunzner,Zora Modrusan,Lars Neumann,Christopher M. Koth,Patrick J. Lupardus,Joshua S. Kaminker,Christopher E. Heise,Pascal Steiner +18 more
TL;DR: Evaluating HDAC inhibitor properties using histone acetylation is not predictive of their function on cellular activity, and a panel of benzamide-containingHDACi are slow tight-binding inhibitors with long residence times unlike the hydroxamate-containing HDACi vorinostat and trichostatin-A.
Journal ArticleDOI
A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo
Jasvinder K. Atwal,Yongmei Chen,Cecilia Chiu,Deborah L. Mortensen,William J. Meilandt,Yichin Liu,Christopher E. Heise,Kwame Hoyte,Wilman Luk,Yanmei Lu,Kun Peng,Ping Wu,Lionel Rouge,Yingnan Zhang,Robert A. Lazarus,Kimberly Scearce-Levie,Weiru Wang,Yan Wu,Marc Tessier-Lavigne,Ryan J. Watts +19 more
TL;DR: This elegant pair of papers demonstrates the therapeutic potential of an anti-BACE1 antibody for treating Alzheimer’s disease but also provides a strategy worthy of the ancient Greeks that could be applied to other therapeutic antibodies that require safe passage into the human brain.